Brown Adipocyte Differentiation via Small Molecule Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective agents to induce the differentiation of brown adipose tissue (BAT) progenitor cells into brown adipocytes in adults, which is crucial for treating metabolic diseases such as obesity, type 2 diabetes, and insulin resistance, as adult humans have minimal BAT activity.
Innovation Solution
The use of specific proteins, peptides, and small molecules to promote the differentiation of BAT progenitor cells into mature brown adipocytes, inducing the expression of UCP1 and other key genes, thereby increasing brown adipocyte mass and improving metabolic health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional methods are used to treat metabolic diseases, then treatment options are limited, but brown adipocyte mass remains insufficient
Solution Approach 1:
The patent changes the chemical parameters by introducing specific small molecules (such as FGF21, FGF15/16 analogs, and other compounds listed in Table 1) that target brown adipocyte progenitor cells. These chemical parameter changes induce differentiation of progenitor cells into mature brown adipocytes, thereby increasing brown adipocyte mass and improving metabolic disease treatment effectiveness.
Solution Approach 2:
The patent uses small molecules as intermediaries that mediate the differentiation process of brown adipocyte progenitor cells. These small molecules act as signaling intermediaries that activate specific pathways (such as FGFR signaling) to promote brown adipocyte differentiation, bridging the gap between conventional treatments and the desired increase in brown adipocyte mass.
2Ease of manufacture
If brown adipocyte progenitor cells are isolated from skeletal muscle, then differentiation can be induced, but effective agents to promote differentiation are lacking
Solution Approach 1:
The patent enables brown adipocyte progenitor cells to self-differentiate into mature brown adipocytes when exposed to specific small molecules. The progenitor cells inherently possess the capability to differentiate, and the small molecules simply provide the necessary signaling cues to activate this self-service differentiation process, achieving reliable differentiation without complex external intervention.
Solution Approach 2:
The patent applies specific chemical parameters (small molecules with defined structures and concentrations) to change the differentiation state of progenitor cells. By controlling the concentration and exposure time of these small molecules, the patent achieves reliable and efficient differentiation of progenitor cells into functional brown adipocytes.
3Use of energy by moving object
If UCP1 expression is increased, then energy expenditure increases, but current methods cannot effectively induce this in adult humans
Solution Approach 1:
The patent uses small molecules as intermediaries to induce UCP1 expression in adult human brown adipocyte progenitor cells. These small molecules (such as FGF21 and its analogs) act as mediators that activate signaling pathways leading to UCP1 gene expression, making the induction process feasible in adults where BAT activity is normally minimal.
Solution Approach 2:
The patent changes the expression parameter of UCP1 by applying specific small molecules that activate transcriptional pathways. The small molecules induce UCP1 gene expression by modulating cellular signaling parameters, thereby increasing energy expenditure through enhanced thermogenic capacity in adult humans.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents effectively increase brown adipocyte differentiation, enhancing insulin sensitivity, reducing fat stores, and improving metabolic health by increasing energy expenditure and glucose tolerance, offering a therapeutic approach for obesity and related disorders.
Implementation Method 1
inducing the expression of UCP1 and other key genes, thereby increasing brown adipocyte mass
Implementation Method 2
UCP1 acts as an uncoupler of oxidative phosphorylation, resulting in dissipation of energy as heat
Implementation Method 3
The sympathetic nervous system stimulates mitochondriogenesis and UCP1 expression and activity
Data Source
AI summary
This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.